INS and type 1 diabetes mellitus: Another open-l abel RCT showed a similar positive impact of teplizumab in new-onset T1DM.36 Teplizumab was found to preserve insulin production and reduce exogenous insulin use in some patients aged between 8 and 30 years with new-onset T1DM for up to 2 years after entering the study.